# OnCo record micromet (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/micromet/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "micromet" ;
  schema:name "Micromet"@en ;
  schema:alternateName "Micromet, Inc."@en, "Micromet AG"@en ;
  schema:description "Micromet developed BiTE antibodies, which link the body's T cells to cancer cells so the T cells can kill them. Amgen bought it in 2012 for blinatumomab, a BiTE antibody for acute lymphoblastic leukaemia."@en ;
  schema:url <https://onco.cc/companies/micromet/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/318154/000119312512024302/d288301dex992.htm>, <https://www.sec.gov/Archives/edgar/data/318154/000119312512100174/d312184dex99a5.htm>, <https://atlasventure.com/portfolio/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:drugs <https://onco.cc/drugs/blinatumomab/> .